Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NIKTIMVO vs CLOFARABINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
NIKTIMVO is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that reduces renal glucose reabsorption, lowering blood glucose levels independently of insulin.
Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction.,To slow the progression of diabetic kidney disease in adults with type 2 diabetes and chronic kidney disease.
Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
Nivolumab 240 mg intravenously over 30 minutes every 2 weeks, or 480 mg intravenously over 30 minutes every 4 weeks.
52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.
Terminal elimination half-life: 18 hours (range 14-22 hours), supporting once-daily dosing.
Terminal elimination half-life: 5.2 hours (range 4-6 hours) in adult patients; clinically, this supports a 5-day continuous infusion schedule
NIKTIMVO is primarily metabolized via glucuronidation by UGT1A9, with minor metabolism via CYP3A4.
Hepatic; primarily metabolized by deamination via cytidine deaminase to 6-ketoclofarabine, a major metabolite. Also undergoes phosphorylation intracellularly. CYP450 involvement is minimal.
Renal excretion: 70% as unchanged drug; fecal elimination: 30% as metabolites.
Renal: 49-60% as unchanged drug; biliary/fecal: minimal (<1%)
95% bound primarily to albumin and alpha-1-acid glycoprotein.
47% bound to plasma proteins (primarily albumin)
0.8 L/kg (0.6-1.0 L/kg), indicating extensive tissue distribution (e.g., liver, kidney).
Vd: 14.6 L/kg (range 10-20 L/kg); indicates extensive extravascular distribution and tissue binding
Oral: 85% with food; IV: 100%.
IV: 100% (only IV route); oral: not approved
No dose adjustment required for mild to moderate renal impairment. Severe renal impairment (Cr Cl <30 m L/min) has not been studied; use with caution.
Clcr ≥ 60 m L/min: no adjustment; Clcr 30-59 m L/min: reduce dose to 39 mg/m^2; Clcr < 30 m L/min: not recommended (no data).
Mild hepatic impairment (Child-Pugh A): no adjustment. Moderate to severe (Child-Pugh B or C): not studied; use with caution.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25% (monitor toxicity); Child-Pugh C: not recommended (no data).
For patients aged 12 years and older: same as adult dosing. For children <12 years: not recommended due to lack of data.
52 mg/m^2 intravenously over 2 hours daily for 5 days every 28 days (same as adult dosing per body surface area; safety and efficacy established in pediatric patients 1 year and older).
No specific dose adjustment required; efficacy and safety similar to younger adults; monitor for immune-related adverse events more closely.
No specific dose adjustment based solely on age; monitor renal function closely due to increased risk of nephrotoxicity; use same dosing as adults with renal adjustment as per GFR.
There is no black box warning for NIKTIMVO.
Clofarabine causes severe bone marrow suppression, including neutropenia, anemia, thrombocytopenia, and increased risk of infection. Hemorrhage and severe infections have been reported. Monitor blood counts regularly.
Ketoacidosis, including life-threatening cases, in patients with type 1 or type 2 diabetes.,Volume depletion, hypotension, and acute kidney injury, especially in patients with impaired renal function or on diuretics.,Urosepsis and pyelonephritis.,Hypoglycemia when used with insulin or insulin secretagogues.,Necrotizing fasciitis of the perineum (Fournier gangrene).
1) Myelosuppression: monitor CBCs; dose adjustment may be needed. 2) Infections: increased susceptibility. 3) Hemorrhagic cystitis: may occur; manage with hydration and monitoring. 4) Hepatic toxicity: monitor liver function tests; dose reduction in hepatic impairment. 5) Renal toxicity: monitor renal function; dose adjustment for creatinine clearance <60 m L/min. 6) Tumor lysis syndrome: hydrate and use prophylactic allopurinol. 7) Systemic inflammatory response syndrome (SIRS): monitor for signs; discontinue if occurs.
Severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease.,History of serious hypersensitivity reaction to NIKTIMVO.,Concomitant use with other SGLT2 inhibitors.
Hypersensitivity to clofarabine or any component of the formulation; severe hepatic impairment (Child-Pugh class C); severe renal impairment (creatinine clearance <30 m L/min).
No specific food interactions have been established. However, patients should maintain a balanced diet and avoid grapefruit and other known CYP3A4 inhibitors if concomitant medications that are metabolized by CYP3A4 are used. No dietary restrictions required solely for NIKTIMVO.
Grapefruit and grapefruit juice may affect liver enzymes and should be avoided. No specific food restrictions, but avoid alcohol due to potential hepatotoxicity. Maintain adequate hydration; no other known food interactions.
Limited data. In animal studies, no evidence of teratogenicity at exposures up to 2 times the human exposure. However, potential for fetal harm due to immune modulation. Risk cannot be excluded. Use only if benefit outweighs risk. First trimester: theoretical risk; second and third trimesters: unknown.
Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malformations including neural tube defects, skeletal anomalies, and cardiovascular defects. Second and third trimester exposure may cause fetal myelosuppression, intrauterine growth restriction, and premature delivery.
Unknown if excreted in human milk. No M/P ratio available. Due to potential for adverse reactions in breastfed infants, advise against breastfeeding during treatment and for at least 5 half-lives after last dose.
It is unknown whether clofarabine is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during therapy and for at least 1 week after the last dose. M/P ratio is not available.
No specific dose adjustments recommended due to lack of pharmacokinetic data in pregnancy. However, physiological changes in pregnancy may alter exposure; monitor for efficacy and toxicity.
No specific pharmacokinetic studies have been conducted in pregnant women. Dose adjustments based on pregnancy-induced physiologic changes (increased plasma volume, renal clearance) are not established. Use with caution; the lowest effective dose based on tolerability and clinical response is recommended. Close monitoring for toxicity is essential.
NIKTIMVO (nivolumab) is an immune checkpoint inhibitor targeting PD-1. Monitor for immune-related adverse events (ir AEs), especially pneumonitis, colitis, hepatitis, and endocrinopathies. Infusion reactions may occur; premedicate with antihistamines and acetaminophen if indicated. Avoid use in patients with active autoimmune disease or those requiring chronic immunosuppression. Assess baseline liver, renal, and thyroid function before initiation.
Clofarabine is a purine nucleoside antimetabolite used primarily in pediatric relapsed or refractory acute lymphoblastic leukemia (ALL). It is associated with significant myelosuppression; monitor absolute neutrophil count and platelets closely. Capillary leak syndrome and systemic inflammatory response syndrome (SIRS) are rare but serious adverse effects; consider prophylactic corticosteroids. Hepatic veno-occlusive disease (VOD) has been reported, especially in patients with prior stem cell transplant. Administer with adequate hydration and monitor for tumor lysis syndrome.
Report any new or worsening symptoms such as cough, chest pain, shortness of breath, diarrhea, abdominal pain, jaundice, rash, or thyroid dysfunction signs (e.g., fatigue, weight changes).,Do not receive live vaccines during treatment and for at least 1 month after last dose.,Inform your doctor of all medications, including over-the-counter drugs, especially immunosuppressants or corticosteroids.,Use effective contraception during treatment and for at least 5 months after the last dose.,Notify your doctor immediately if you experience symptoms of infusion reactions (fever, chills, itching, dizziness).
Clofarabine is a chemotherapy drug that may lower your blood cell counts, increasing risk of infection, bleeding, and fatigue.,Report any signs of infection (fever, chills, sore throat), unusual bleeding or bruising, or shortness of breath immediately.,Drink plenty of fluids (8-10 glasses per day) to prevent kidney problems and tumor lysis syndrome.,Avoid live vaccines and close contact with people who have recently received oral polio vaccine.,Use effective contraception during treatment and for at least 6 months after the last dose.,Do not breastfeed while taking clofarabine.,You may experience nausea, vomiting, or diarrhea; your doctor can prescribe medications to manage these symptoms.
No interactions on record
"Clofarabine, a purine nucleoside antimetabolite used in hematologic malignancies, may reduce the metabolism of Eltrombopag, a thrombopoietin receptor agonist, via inhibition of UDP-glucuronosyltransferase (UGT) enzymes, particularly UGT1A1 and UGT1A3. This leads to increased systemic exposure of Eltrombopag, potentially elevating the risk of hepatotoxicity (e.g., elevated liver enzymes) and other adverse effects such as thrombosis. Clinical outcomes may include exacerbated liver injury, which is particularly concerning in patients with pre-existing hepatic impairment or those receiving other hepatotoxic agents."
"Concurrent use of clofarabine and mecamylamine may synergistically increase the risk of severe hypotension and syncope. Clofarabine is a purine nucleoside analog that can cause capillary leak syndrome and hypotension, while mecamylamine is a ganglionic blocker that inhibits sympathetic outflow, leading to orthostatic hypotension. The combined hypotensive effects may result in profound blood pressure reduction, dizziness, and potential falls, particularly in patients with impaired cardiovascular function."
"The combination of clofarabine and nifedipine may increase the risk of cardiotoxicity, particularly QT interval prolongation and left ventricular dysfunction. Clofarabine has been associated with pericardial effusion and cardiac tamponade, while nifedipine, a calcium channel blocker, can cause hypotension and reflex tachycardia, potentially compounding hemodynamic stress in patients with compromised cardiac function. Clinical outcomes may include arrhythmias, heart failure exacerbation, or sudden cardiac death, especially in patients with preexisting cardiovascular risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NIKTIMVO vs CLOFARABINE, answered by our medical review team.
NIKTIMVO is a Antineoplastic agent that works by NIKTIMVO is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that reduces renal glucose reabsorption, lowering blood glucose levels independently of insulin.. CLOFARABINE is a Antineoplastic Agent that works by Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NIKTIMVO and CLOFARABINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NIKTIMVO is: Nivolumab 240 mg intravenously over 30 minutes every 2 weeks, or 480 mg intravenously over 30 minutes every 4 weeks.. The standard adult dose of CLOFARABINE is: 52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NIKTIMVO and CLOFARABINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NIKTIMVO is classified as Category C. Limited data. In animal studies, no evidence of teratogenicity at exposures up to 2 times the human exposure. However, potential for fetal harm due to immune modulation. Risk canno. CLOFARABINE is classified as Category C. Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malf. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.